These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23667506)

  • 1. Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome.
    Pedersen J; Jensen TB; Carlsen TH; Schønning K; Christensen PB; Laursen AL; Krarup H; Bukh J; Weis N
    PLoS One; 2013; 8(5):e62674. PubMed ID: 23667506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR.
    Vigón L; Vázquez-Morón S; Berenguer J; González-García J; Jiménez-Sousa MÁ; Guardiola JM; Crespo M; de Los Santos I; Von Wichmann MA; Carrero A; Yélamos MB; Gómez J; Resino S; Martínez I;
    Sci Rep; 2019 Aug; 9(1):12163. PubMed ID: 31434968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing antibodies in patients with chronic hepatitis C and correlation to liver cirrhosis and estimated duration of infection.
    Pedersen J; Lundbo LF; Krarup H; Bukh J; Weis N
    J Med Virol; 2016 Oct; 88(10):1791-803. PubMed ID: 27027386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a.
    Carlsen TH; Pedersen J; Prentoe JC; Giang E; Keck ZY; Mikkelsen LS; Law M; Foung SK; Bukh J
    Hepatology; 2014 Nov; 60(5):1551-62. PubMed ID: 25043937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.
    Velázquez-Moctezuma R; Galli A; Law M; Bukh J; Prentoe J
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations.
    Scheel TK; Gottwein JM; Carlsen TH; Li YP; Jensen TB; Spengler U; Weis N; Bukh J
    J Virol; 2011 Mar; 85(6):2891-906. PubMed ID: 21177811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization.
    Scheel TK; Gottwein JM; Jensen TB; Prentoe JC; Hoegh AM; Alter HJ; Eugen-Olsen J; Bukh J
    Proc Natl Acad Sci U S A; 2008 Jan; 105(3):997-1002. PubMed ID: 18195353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs.
    Gottwein JM; Scheel TK; Jensen TB; Lademann JB; Prentoe JC; Knudsen ML; Hoegh AM; Bukh J
    Hepatology; 2009 Feb; 49(2):364-77. PubMed ID: 19148942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies.
    Pedersen J; Carlsen TH; Prentoe J; Ramirez S; Jensen TB; Forns X; Alter H; Foung SK; Law M; Gottwein J; Weis N; Bukh J
    Hepatology; 2013 Nov; 58(5):1587-97. PubMed ID: 23729237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.
    Swann RE; Cowton VM; Robinson MW; Cole SJ; Barclay ST; Mills PR; Thomson EC; McLauchlan J; Patel AH
    J Virol; 2016 May; 90(9):4530-4543. PubMed ID: 26912610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A point mutation at Asn-534 that disrupts a conserved N-glycosylation motif of the E2 glycoprotein of hepatitis C virus markedly enhances the sensitivity to antibody neutralization.
    Sasayama M; Shoji I; Adianti M; Jiang DP; Deng L; Saito T; Watanabe H; Kawata S; Aoki C; Hotta H
    J Med Virol; 2012 Feb; 84(2):229-34. PubMed ID: 22170542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of longitudinal change in hepatitis C virus neutralization titers correlate with the outcome of peginterferon and ribavirin combination therapy.
    Lin J; Wang W; Xu Y; Di Bisceglie AM; Fan X
    J Med Virol; 2015 May; 87(5):821-8. PubMed ID: 25652546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance.
    Serre SB; Krarup HB; Bukh J; Gottwein JM
    J Virol; 2013 Dec; 87(23):12776-93. PubMed ID: 24049176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of neutralizing antibodies against hepatitis C virus in patients who were treated with pegylated-interferon plus ribavirin.
    Sasayama M; Deng L; Kim SR; Ide Y; Shoji I; Hotta H
    Kobe J Med Sci; 2010 Sep; 56(2):E60-6. PubMed ID: 21063147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
    Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P;
    J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Approach To Display Structural Proteins of Hepatitis C Virus Quasispecies in Patients Reveals a Key Role of E2 HVR1 in Viral Evolution.
    Tong Y; Li Q; Li R; Xu Y; Pan Y; Niu J; Zhong J
    J Virol; 2020 Aug; 94(17):. PubMed ID: 32554700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
    Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
    Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
    Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C Virus-Escape Studies for Human Monoclonal Antibody AR4A Reveal Isolate-Specific Resistance and a High Barrier to Resistance.
    Velázquez-Moctezuma R; Galli A; Law M; Bukh J; Prentoe J
    J Infect Dis; 2019 Jan; 219(1):68-79. PubMed ID: 30102355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection.
    Jensen TB; Gottwein JM; Scheel TK; Hoegh AM; Eugen-Olsen J; Bukh J
    J Infect Dis; 2008 Dec; 198(12):1756-65. PubMed ID: 19032070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.